These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 38430529)

  • 21. Extracting and Benchmarking Emerging Adverse Outcome Pathway Knowledge.
    Pollesch NL; Villeneuve DL; O'Brien JM
    Toxicol Sci; 2019 Apr; 168(2):349-364. PubMed ID: 30715536
    [TBL] [Abstract][Full Text] [Related]  

  • 22. AOP-DB: A database resource for the exploration of Adverse Outcome Pathways through integrated association networks.
    Pittman ME; Edwards SW; Ives C; Mortensen HM
    Toxicol Appl Pharmacol; 2018 Mar; 343():71-83. PubMed ID: 29454060
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Collaborative efforts are needed among the scientific community to advance the adverse outcome pathway concept in areas of radiation risk assessment.
    Chauhan V; Villeneuve D; Cool D
    Int J Radiat Biol; 2021; 97(6):815-823. PubMed ID: 33253609
    [TBL] [Abstract][Full Text] [Related]  

  • 24. AOP-helpFinder webserver: a tool for comprehensive analysis of the literature to support adverse outcome pathways development.
    Jornod F; Jaylet T; Blaha L; Sarigiannis D; Tamisier L; Audouze K
    Bioinformatics; 2022 Jan; 38(4):1173-1175. PubMed ID: 34718414
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An integrative data-centric approach to derivation and characterization of an adverse outcome pathway network for cadmium-induced toxicity.
    Sahoo AK; Chivukula N; Ramesh K; Singha J; Marigoudar SR; Sharma KV; Samal A
    Sci Total Environ; 2024 Apr; 920():170968. PubMed ID: 38367714
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The future trajectory of adverse outcome pathways: a commentary.
    Sewell F; Gellatly N; Beaumont M; Burden N; Currie R; de Haan L; Hutchinson TH; Jacobs M; Mahony C; Malcomber I; Mehta J; Whale G; Kimber I
    Arch Toxicol; 2018 Apr; 92(4):1657-1661. PubMed ID: 29549413
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Challenge for Adverse Outcome Pathway (AOP)-based Chemical Safety Assessment].
    Yamada T; Ashikaga T; Kojima H; Hirose A
    Yakugaku Zasshi; 2020; 140(4):481-484. PubMed ID: 32238628
    [TBL] [Abstract][Full Text] [Related]  

  • 28. AOPERA: A proposed methodology and inventory of effective tools to link chemicals to adverse outcome pathways.
    Rycroft TE; Foran CM; Thrash A; Cegan JC; Zollinger R; Linkov I; Perkins EJ; Garcia-Reyero N
    ALTEX; 2020; 37(1):64-74. PubMed ID: 31453632
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Radiation adverse outcome pathways (AOPs) are on the horizon: advancing radiation protection through an international Horizon-Style exercise.
    Burtt JJ; Leblanc J; Randhawa K; Ivanova A; Rudd MA; Wilkins R; Azzam EI; Hecker M; Horemans N; Vandenhove H; Adam-Guillermin C; Armant O; Klokov D; Audouze K; Kaiser JC; Moertl S; Lumniczky K; Tanaka IB; Yamada Y; Hamada N; Al-Nabulsi I; Preston RJ; Bouffler S; Applegate K; Cool D; Beaton D; Tollefsen KE; Garnier-Laplace J; Laurier D; Chauhan V
    Int J Radiat Biol; 2022; 98(12):1763-1776. PubMed ID: 36067511
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Linking Mitochondrial Dysfunction to Organismal and Population Health in the Context of Environmental Pollutants: Progress and Considerations for Mitochondrial Adverse Outcome Pathways.
    Dreier DA; Mello DF; Meyer JN; Martyniuk CJ
    Environ Toxicol Chem; 2019 Aug; 38(8):1625-1634. PubMed ID: 31034624
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Introducing WikiPathways as a Data-Source to Support Adverse Outcome Pathways for Regulatory Risk Assessment of Chemicals and Nanomaterials.
    Martens M; Verbruggen T; Nymark P; Grafström R; Burgoon LD; Aladjov H; Torres Andón F; Evelo CT; Willighagen EL
    Front Genet; 2018; 9():661. PubMed ID: 30622555
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Development of an adverse outcome pathway network for nephrotoxicity.
    Barnes DA; Firman JW; Belfield SJ; Cronin MTD; Vinken M; Janssen MJ; Masereeuw R
    Arch Toxicol; 2024 Mar; 98(3):929-942. PubMed ID: 38197913
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Why adverse outcome pathways need to be FAIR.
    Wittwehr C; Clerbaux LA; Edwards S; Angrish M; Mortensen H; Carusi A; Gromelski M; Lekka E; Virvilis V; Martens M; Bonino da Silva Santos LO; Nymark P
    ALTEX; 2024 Jan; 41(1):50-56. PubMed ID: 37528748
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Overview of Adverse Outcome Pathways and Current Applications on Nanomaterials.
    Rolo D; Tavares A; Vital N; Silva MJ; Louro H
    Adv Exp Med Biol; 2022; 1357():415-439. PubMed ID: 35583654
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Development of an adverse outcome pathway network for breast cancer: a comprehensive representation of the pathogenesis, complexity and diversity of the disease.
    Del'haye GG; Nulmans I; Bouteille SP; Sermon K; Wellekens B; Rombaut M; Vanhaecke T; Vander Heyden Y; De Kock J
    Arch Toxicol; 2022 Nov; 96(11):2881-2897. PubMed ID: 35927586
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Pragmatic Approach to Adverse Outcome Pathway Development and Evaluation.
    Svingen T; Villeneuve DL; Knapen D; Panagiotou EM; Draskau MK; Damdimopoulou P; O'Brien JM
    Toxicol Sci; 2021 Nov; 184(2):183-190. PubMed ID: 34534351
    [TBL] [Abstract][Full Text] [Related]  

  • 37. When Are Adverse Outcome Pathways and Associated Assays "Fit for Purpose" for Regulatory Decision-Making and Management of Chemicals?
    Coady K; Browne P; Embry M; Hill T; Leinala E; Steeger T; Maślankiewicz L; Hutchinson T
    Integr Environ Assess Manag; 2019 Jul; 15(4):633-647. PubMed ID: 30908812
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Building a Network of Adverse Outcome Pathways (AOPs) Incorporating the Tau-Driven AOP Toward Memory Loss (AOP429).
    Tsamou M; Roggen EL
    J Alzheimers Dis Rep; 2022; 6(1):271-296. PubMed ID: 35891639
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Investigation of a derived adverse outcome pathway (AOP) network for endocrine-mediated perturbations.
    Ravichandran J; Karthikeyan BS; Samal A
    Sci Total Environ; 2022 Jun; 826():154112. PubMed ID: 35219661
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identification of neurotoxicology (NT)/developmental neurotoxicology (DNT) adverse outcome pathways and key event linkages with in vitro DNT screening assays.
    Pitzer EM; Shafer TJ; Herr DW
    Neurotoxicology; 2023 Dec; 99():184-194. PubMed ID: 37866692
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.